Gout: one year in review 2023.
Journal
Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
17
11
2023
accepted:
08
01
2024
medline:
2
2
2024
pubmed:
2
2
2024
entrez:
2
2
2024
Statut:
ppublish
Résumé
Gout is a chronic joint disease caused by the deposition of monosodium urate crystals into and around the articular tissues. In the last two years, new insights regarding diagnosis, genetic involvement, pathogenesis, comorbidities, and clinical data, have allowed the identification of new strategies to improve the control of the disease and its flares. In keeping, the discover of new mechanisms concerning crystal-induced inflammation have suggested new ways for the management not only of gout, but also other systemic diseases, mainly including renal and cardiovascular disorders. In this context it is very representative the case of colchicine which, given the surprising results obtained both in laboratory and clinical experiments, has recently received by FDA the approval for the prevention of cardiovascular disorders.
Identifiants
pubmed: 38306017
pii: 20578
doi: 10.55563/clinexprheumatol/uhyzcr
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM